ALRN - Aileron Therapeutics Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 2.86 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): -7.86 StockBond Score: -5.00 Company Description Aileron Therapeutics Inc operates as a clinical stage chemoprotection oncology company in the United States The company is developing ALRN6924 which is in Phase 1 trial for solid tumor and lymphoma Phase 2a clinical trial to treat peripheral Tcell lymphoma Phase I clinical trial for the treatment of acute myeloid leukemia AML and advanced myelodysplastic syndrome MDS Phase 1b trial to test the combination of ALRN6924 and cytarabine or AraC in patients with MDS and a Phase 2a combination trial of ALRN6924 and palbociclib in patients with tumors harboring MDM2 amplifications coamplifications as well as for patients with p53mutated small cell lung cancer that has completed Phase 1b clinical trial It has a license agreement with DanaFarber Cancer Institute and Harvard College and Umicore Precious Metals Chemistry USA LLC The company was formerly known as Renegade Therapeutics Inc and changed its name to Aileron Therapeutics Inc in February 2007 Aileron Therapeutics Inc was incorporated in 2001 and is based in Boston Massachusetts